IL17A and Peri-Implantitis: In conclusion, our study demonstrates that after three months of therapy, there was a significant reduction in the expression of cytokines in the peri-implant crevicular fluid of patients with peri-implant mucositis (IL-17A and TNF-α) and peri-implantitis (IL -1β, IL-6, and TNF-α).